Last updated on July 2019

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced Platinum-Ineligible Bladder Cancer (BAYOU)


Brief description of study

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer

Detailed Study Description

This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative global study to determine the efficacy and safety of durvalumab + olaparib combination therapy versus durvalumab + placebo (durvalumab monotherapy) as first-line treatment in patients ineligible for platinum-based chemotherapy with unresectable Stage IV urothelial cancer (UC).

Clinical Study Identifier: NCT03459846

Find a site near you

Start Over

Research Site

San Juan, Puerto Rico
1.81miles
  Connect »